Croma-Pharma GmbH appears in FDA device records as the applicant behind saypha® ChiQ™, filed under product code LMH, the code FDA labels "Implant, Dermal, For Aesthetic Use." The original premarket approval, P250021, was filed June 26, 2025 and decided June 12, 2026, with the approval order addressed to the applicant through outside counsel. Two later supplements, both post-approval study protocol submissions, were decided in October 2026. The record identifies an applicant and a device; it does not establish corporate ownership, a parent company or a commercial launch. [3][5][9]
The device and its documented composition
The directions for use describe saypha® ChiQ™ as a sterile, biodegradable, non-pyrogenic, viscoelastic, clear, colorless, homogeneous gel used as a soft tissue filler. Its hyaluronic acid is produced by Streptococcus species of bacteria and cross-linked with BDDE (1,4-butanediol diglycidyl ether), at a sodium hyaluronate concentration of 23 mg/mL. The same labeling names Obagi Cosmeceuticals LLC of Long Beach, California, and states that ChIQ™ is a trademark of that company, while saypha® is a registered trademark of CROMA-PHARMA GmbH. [9]
FDA's summary of safety and effectiveness data lists the device generic name as injectable dermal filler, the trade name as saypha® ChIQ™, and the applicant as CROMA-PHARMA GmbH at Industriezeile 6, 2100 Leobendorf, Austria. That address appears as the applicant's address in the filing, not as a verified corporate headquarters. [4]
Indication and approval scope
The approval order states that saypha® ChIQ™ is indicated for cheek augmentation and restoring midface volume deficits in patients over the age of 21, administered by subcutaneous and/or supraperiosteal injection. The filing was received June 26, 2025, amended April 24, 2026, and approved June 12, 2026, with a Federal Register notice date of the same day and docket number 26M-6734. FDA's summary records no panel recommendation. [3][4][5]
The approval order also states that the device is subject to the Quality Management System Regulation at 21 CFR Part 820, citing ISO 13485 clauses on design controls, nonconforming product and corrective action. FDA's summary states that the applicant's manufacturing facility was inspected and found in compliance with the quality system regulation in effect at the time of inspection. [4][5]
Post-approval study supplements
Supplement S001, received July 10, 2026 and decided October 7, 2026, records approval of the scale validation protocol for the post-approval study referenced in the approval order. Both supplements are listed on the Normal 180 Day Track No User Fee, with no expedited review flag and the General, Plastic Surgery advisory committee. [2][8]
Supplement S002, also received July 10, 2026 and decided October 8, 2026, records approval of the post-approval study protocol submitted to comply with the conditions of approval in the P250021 order. The FDA post-approval studies database describes the agency's authority to require sponsors to perform such studies. [1][10]
What the filing record covers
The supplied collection holds three linked records, all on the PMA pathway and all with an approval decision; the smaller record sample of three shows the same approval count. These figures describe the supplied filings as of the snapshot date and are not measures of total portfolio, sales or safety performance. No recall records appear in the supplied sample. [1][2][3]



